Aeglea Bio Therapeutics Inc (AGLE) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have earned an average rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $26.00.

Several research firms have recently commented on AGLE. Wells Fargo & Co cut shares of Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 4th. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 11th.

In other news, insider Aaron Schuchart sold 6,000 shares of the stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $9.50, for a total transaction of $57,000.00. Following the sale, the insider now directly owns 8,400 shares of the company’s stock, valued at $79,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 18.30% of the stock is owned by corporate insiders.



Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Aeglea Bio Therapeutics by 3,257.3% in the second quarter. BlackRock Inc. now owns 822,505 shares of the biotechnology company’s stock valued at $8,703,000 after acquiring an additional 798,006 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Aeglea Bio Therapeutics by 417.8% in the second quarter. Renaissance Technologies LLC now owns 528,200 shares of the biotechnology company’s stock valued at $5,588,000 after acquiring an additional 426,200 shares during the last quarter. Millennium Management LLC boosted its stake in Aeglea Bio Therapeutics by 542.2% in the second quarter. Millennium Management LLC now owns 476,478 shares of the biotechnology company’s stock valued at $5,041,000 after acquiring an additional 402,288 shares during the last quarter. Orbimed Advisors LLC boosted its stake in Aeglea Bio Therapeutics by 26.9% in the second quarter. Orbimed Advisors LLC now owns 1,865,524 shares of the biotechnology company’s stock valued at $19,737,000 after acquiring an additional 396,000 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in Aeglea Bio Therapeutics by 20.0% in the second quarter. Nantahala Capital Management LLC now owns 2,213,052 shares of the biotechnology company’s stock valued at $23,414,000 after acquiring an additional 368,379 shares during the last quarter. 66.24% of the stock is currently owned by institutional investors and hedge funds.

AGLE opened at $8.60 on Wednesday. Aeglea Bio Therapeutics has a one year low of $3.75 and a one year high of $12.00.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.10). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 57.15%. The company had revenue of $2.38 million for the quarter. On average, research analysts expect that Aeglea Bio Therapeutics will post -1.8 earnings per share for the current year.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Read More: What is the float in trading stocks?

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply